Classical Hodgkin Lymphoma research hub
6 indexed studies · 5 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
This study looks at new ways to treat Hodgkin lymphoma, a type of cancer that affects the immune system. Researchers are testing different combinations of medicines to see how well they work and if they are safe. The main goal is to see if these treatments can make the cancer go away completely.
Spain · Czechia · Italy - recruitingTherapeutic exploratory (Phase II)
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
This study looks at a new treatment called pembrolizumab, combined with standard chemotherapy, for adults recently diagnosed with classical Hodgkin lymphoma. Researchers want to see how many patients go into complete remission at the end of the treatment plan.
France · Poland · Spain - active not recruitingPHASE2
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
This study looks at combining a new medicine called Nivolumab with radiotherapy for Hodgkin Lymphoma that has come back or not responded to previous treatment. It aims to see if this combination works better than Nivolumab alone by using radiation to boost the body's immune response.
Germany - recruiting
European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
This study is looking for better ways to check how well treatment is working for children and young people with a type of cancer called Hodgkin lymphoma. It hopes to use simple blood tests to find tiny bits of cancer DNA, which could help doctors give the best possible care.
France - recruitingPHASE1, PHASE2
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
This study looks at a medicine called pembrolizumab for children aged 6 months to 17 years with certain advanced cancers that haven't responded to other treatments. It's an immunotherapy that helps the body's immune system fight cancer, and researchers want to see if it can shrink these cancers.
United States · Brazil · France - recruitingPHASE2
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
This study looks at a new way to treat early-stage Hodgkin Lymphoma using a drug called Tislelizumab. The goal is to find an effective treatment that causes fewer side effects than traditional chemotherapy and radiation, especially for younger patients.
Germany